US9254318B2 - High titer recombinant influenza viruses for vaccines - Google Patents
High titer recombinant influenza viruses for vaccines Download PDFInfo
- Publication number
- US9254318B2 US9254318B2 US11/729,557 US72955707A US9254318B2 US 9254318 B2 US9254318 B2 US 9254318B2 US 72955707 A US72955707 A US 72955707A US 9254318 B2 US9254318 B2 US 9254318B2
- Authority
- US
- United States
- Prior art keywords
- influenza virus
- vector
- virus
- operably linked
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/729,557 US9254318B2 (en) | 2006-03-31 | 2007-03-29 | High titer recombinant influenza viruses for vaccines |
US15/000,851 US9926535B2 (en) | 2006-03-31 | 2016-01-19 | High titer recombinant influenza viruses for vaccines |
US15/905,454 US20190048324A1 (en) | 2006-03-31 | 2018-02-26 | High titer recombinant influenza viruses for vaccines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78776606P | 2006-03-31 | 2006-03-31 | |
US11/729,557 US9254318B2 (en) | 2006-03-31 | 2007-03-29 | High titer recombinant influenza viruses for vaccines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/000,851 Continuation US9926535B2 (en) | 2006-03-31 | 2016-01-19 | High titer recombinant influenza viruses for vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
US20070231348A1 US20070231348A1 (en) | 2007-10-04 |
US9254318B2 true US9254318B2 (en) | 2016-02-09 |
Family
ID=38476021
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/729,557 Active US9254318B2 (en) | 2006-03-31 | 2007-03-29 | High titer recombinant influenza viruses for vaccines |
US15/000,851 Active US9926535B2 (en) | 2006-03-31 | 2016-01-19 | High titer recombinant influenza viruses for vaccines |
US15/905,454 Abandoned US20190048324A1 (en) | 2006-03-31 | 2018-02-26 | High titer recombinant influenza viruses for vaccines |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/000,851 Active US9926535B2 (en) | 2006-03-31 | 2016-01-19 | High titer recombinant influenza viruses for vaccines |
US15/905,454 Abandoned US20190048324A1 (en) | 2006-03-31 | 2018-02-26 | High titer recombinant influenza viruses for vaccines |
Country Status (7)
Country | Link |
---|---|
US (3) | US9254318B2 (fr) |
EP (1) | EP2010557B1 (fr) |
JP (3) | JP2009532352A (fr) |
CN (1) | CN101472941B (fr) |
AU (1) | AU2007245192B2 (fr) |
CA (1) | CA2647985C (fr) |
WO (1) | WO2007126810A2 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
US9926535B2 (en) | 2006-03-31 | 2018-03-27 | Wisconsin Alumni Research Foundation (Warf) | High titer recombinant influenza viruses for vaccines |
US9950057B2 (en) | 2013-07-15 | 2018-04-24 | Wisconsin Alumni Research Foundation (Warf) | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs |
US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US10119124B2 (en) | 2007-06-18 | 2018-11-06 | Wisconsin Alumni Research Foundation (Warf) | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
US10808229B2 (en) | 2009-10-26 | 2020-10-20 | Wisconsin Alumni Research Foundation (“WARF”) | High titer recombinant influenza viruses with enhanced replication in vero cells |
US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
US11241492B2 (en) | 2019-01-23 | 2022-02-08 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to genes in influenza viruses |
US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
US11851648B2 (en) | 2019-02-08 | 2023-12-26 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079273A2 (fr) * | 2000-04-14 | 2001-10-25 | Wisconsin Alumni Research Foundation | Virus contenant une proteine mutante de canal ionique |
EP1364006A2 (fr) | 2001-02-23 | 2003-11-26 | Wisconsin Alumni Research Foundation | Methode d'identification de cellulles mutantes avec acid sialic modifie |
BRPI0307679A2 (pt) * | 2002-02-13 | 2016-11-08 | Wisconsin Alumni Res Found | vetor viral de influenza, vírus recombinate de influenza, molécula isolada de ácido nucleico e métodos para expressar um segmento heterólogo de ácido nucleico em uma célula e para preparar vírus semelhante a influenza incompetente na replicação. |
WO2004094466A2 (fr) * | 2003-04-23 | 2004-11-04 | Wisconsin Alumni Research Foundation | Virus codant une proteine membranaire mutante |
WO2004112831A2 (fr) * | 2003-05-28 | 2004-12-29 | Wisconsin Alumni Research Foundation | Virus influenza de recombinaison a titre eleve pour vaccins et therapie genique |
US9072701B2 (en) * | 2006-04-21 | 2015-07-07 | St. Jude Children's Research Hospital | Avian influenza viruses, vaccines, compositions, formulations, and methods |
US8597661B2 (en) * | 2007-05-04 | 2013-12-03 | Wisconsin Alumni Research Foundation | Neuraminidase-deficient live influenza vaccines |
US9005632B2 (en) * | 2009-11-20 | 2015-04-14 | Takeda Vaccines, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains |
CN101914498B (zh) * | 2010-02-08 | 2013-07-03 | 中国农业科学院上海兽医研究所 | 稳定表达高致病力禽流感病毒ha蛋白的mdck细胞系及其用途 |
US9173933B2 (en) * | 2010-10-15 | 2015-11-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara influenza vaccine |
EP2747778B1 (fr) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Virus de la grippe ayant un segment génique pb2 mutant en tant que vaccins vivants atténués |
AU2014203051C1 (en) * | 2012-03-02 | 2016-09-01 | Seqirus UK Limited | Influenza Virus Reassortment |
EP2820126B1 (fr) * | 2012-03-02 | 2017-05-17 | Seqirus UK Limited | Réassortiment du virus de la grippe |
US9803251B2 (en) * | 2012-05-03 | 2017-10-31 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of detecting influenza virus |
CA2886769C (fr) * | 2012-10-05 | 2022-01-04 | Denka Seiken Co., Ltd. | Methode de mesure de l'hemagglutinine provenant du virus de la grippe |
CN105120893B (zh) * | 2012-12-03 | 2018-11-13 | 诺华股份有限公司 | 流感病毒重配 |
US10232031B2 (en) | 2013-03-13 | 2019-03-19 | Seqirus UK Limited | Influenza virus reassortment |
CN103865923B (zh) * | 2014-01-28 | 2017-04-26 | 中国人民解放军第三0二医院 | 流感病毒为载体的HAdV嵌合疫苗的制备及其应用 |
CN105985446B (zh) * | 2014-10-17 | 2019-05-14 | 中国农业大学 | 可优化病毒复制的培养基 |
CN104372023B (zh) * | 2014-11-10 | 2017-02-08 | 中国农业大学 | 一种拯救流感病毒的方法 |
EP3341018A1 (fr) | 2015-08-28 | 2018-07-04 | Wisconsin Alumni Research Foundation | Génération de virus de la grippe infectieux à partir de pseudo-particules virales (vlp) |
PT3436593T (pt) * | 2016-03-28 | 2023-01-31 | Ultragenyx Pharmaceutical Inc | Métodos de inativação pelo calor de adenovírus |
EP3471767A4 (fr) | 2016-06-15 | 2020-01-15 | Icahn School of Medicine at Mount Sinai | Hémagglutinines du virus de la grippe et utilisations de celles-ci |
EP3606555A4 (fr) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | Anticorps anti-neuraminidase du virus influenza de type b et leurs utilisations |
US11197926B2 (en) * | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
US20220249652A1 (en) * | 2019-06-26 | 2022-08-11 | Icahn School Of Medicine At Mount Sinai | Influenza virus neuraminidase and uses thereof |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000060050A2 (fr) | 1999-04-06 | 2000-10-12 | Wisconsin Alumni Research Foundation | Virus de l'influenza recombinants pour vaccins et traitement genetique |
WO2001083794A2 (fr) | 2000-04-28 | 2001-11-08 | St. Jude Children's Research Hospital | Systeme de transfection d'adn servant a generer des virus de la grippe infectieuse |
EP1201760A1 (fr) | 2000-10-30 | 2002-05-02 | ARTEMIS Pharmaceuticals GmbH | Vecteur viral Influenza pour cellules dendritiques |
US20030035814A1 (en) | 1999-04-06 | 2003-02-20 | Yoshihiro Kawaoka | Recombinant influenza viruses for vaccines and gene therapy |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
WO2003068923A2 (fr) | 2002-02-13 | 2003-08-21 | Wisconsin Alumni Research Foundation | Signal d'incorporation de vecteurs de virus de la grippe |
WO2003091401A2 (fr) | 2002-04-26 | 2003-11-06 | Medimmune Vaccines, Inc. | Systeme multiplasmide de production de virus influenza |
WO2004112831A2 (fr) | 2003-05-28 | 2004-12-29 | Wisconsin Alumni Research Foundation | Virus influenza de recombinaison a titre eleve pour vaccins et therapie genique |
WO2005062820A2 (fr) | 2003-12-23 | 2005-07-14 | Medimmune Vaccines, Inc | Systeme a plasmides multiples pour la production du virus de la grippe |
JP2005245302A (ja) | 2004-03-04 | 2005-09-15 | Kanazawa Univ Tlo Inc | 組換えインフルエンザウイルスおよびそれを用いたワクチン |
US7037707B2 (en) * | 2003-09-04 | 2006-05-02 | St. Jude Children's Research Hospital | Method for generating influenza viruses and vaccines |
US20070231348A1 (en) * | 2006-03-31 | 2007-10-04 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
US7507411B2 (en) * | 2006-06-23 | 2009-03-24 | University Of Saskatchewan | Attenuated influenza NS1 variants |
AU2012204138B2 (en) | 2006-03-31 | 2014-02-06 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4071618A (en) | 1974-09-03 | 1978-01-31 | Research Foundation For Microbial Diseases Of Osaka University | Process for preparing virus disease live vaccines |
JPS57136528A (en) | 1981-02-09 | 1982-08-23 | Hayashibara Biochem Lab Inc | Preparation of viral vaccine |
NZ219515A (en) | 1987-02-10 | 1989-09-27 | Wellcome Found | Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope |
US5840520A (en) | 1989-08-28 | 1998-11-24 | Aviron | Recombinant negative strand RNA virus expression systems |
US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
ES2210273T5 (es) | 1994-07-18 | 2010-03-29 | Conzelmann, Karl-Klaus, Prof. Dr. | Virus con arn de cadena negativa no segmentado recombinante infeccioso. |
US5716821A (en) | 1994-09-30 | 1998-02-10 | Uab Research Foundation | Prevention and treatment of respiratory tract disease |
US5789229A (en) | 1994-09-30 | 1998-08-04 | Uab Research Foundation | Stranded RNA virus particles |
DE69510207T3 (de) | 1995-08-09 | 2007-02-15 | Schweiz. Serum- & Impfinstitut Bern | Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren |
US6037348A (en) | 1996-02-09 | 2000-03-14 | Eli Lilly And Company | Inhibition of viral replication |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
US5994526A (en) | 1996-06-21 | 1999-11-30 | Plant Genetic Systems | Gene expression in plants |
BRPI9710363B8 (pt) | 1996-07-15 | 2021-07-06 | Us Gov Health & Human Serv | partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso. |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
KR100702523B1 (ko) | 1997-05-23 | 2007-04-04 | 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 | 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법 |
JP5132851B2 (ja) | 1997-08-05 | 2013-01-30 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用 |
KR100281676B1 (ko) | 1997-11-29 | 2001-04-02 | 신동권 | 신규한독감생백신바이러스 |
US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
EP1035209A1 (fr) | 1999-03-06 | 2000-09-13 | ARTEMIS Pharmaceuticals GmbH | Virus influenza recombinants stables dépourvus de virus auxiliaire |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6686168B1 (en) | 1999-11-04 | 2004-02-03 | Zymogenetics, Inc. | Cell surface display of proteins by recombinant host cells |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
KR100797547B1 (ko) | 2000-03-03 | 2008-01-24 | 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
WO2001079273A2 (fr) | 2000-04-14 | 2001-10-25 | Wisconsin Alumni Research Foundation | Virus contenant une proteine mutante de canal ionique |
EP1364006A2 (fr) | 2001-02-23 | 2003-11-26 | Wisconsin Alumni Research Foundation | Methode d'identification de cellulles mutantes avec acid sialic modifie |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
US6951752B2 (en) | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
WO2003076462A1 (fr) | 2002-03-08 | 2003-09-18 | Crucell Holland B.V. | Utilisation de trypsine recombinante dans la production de vaccins |
US7465456B2 (en) | 2002-04-26 | 2008-12-16 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
DK2287288T3 (da) | 2002-07-09 | 2013-01-07 | Baxter Int | Medium frit for animalsk protein til dyrkning af celler |
WO2004094466A2 (fr) | 2003-04-23 | 2004-11-04 | Wisconsin Alumni Research Foundation | Virus codant une proteine membranaire mutante |
KR20060026854A (ko) | 2003-05-28 | 2006-03-24 | 위스콘신 얼럼나이 리서어치 화운데이션 | PolⅡ 프로모터 및 리보자임을 갖는 재조합 인플루엔자벡터 |
WO2005018539A2 (fr) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Hemagglutinine du virus de la grippe et variantes de la neuraminidase |
KR20070060049A (ko) | 2004-05-20 | 2007-06-12 | 아이디 바이오메디칼 코포레이션 | 인플루엔자 백신의 제조방법 |
ES2386272T3 (es) | 2004-09-09 | 2012-08-16 | Novartis Vaccines And Diagnostics Gmbh | Reducción de riesgos iatrogénicos potenciales asociados a las vacunas antigripales |
KR20070086344A (ko) | 2004-11-19 | 2007-08-27 | 위스콘신 얼럼나이 리서어치 화운데이션 | 탠덤 전사 유닛을 갖는 재조합 인플루엔자 벡터 |
ATE547511T1 (de) | 2004-12-23 | 2012-03-15 | Medimmune Llc | Nichttumorbildende mdck-zellinie zur vermehrung von viren |
BRPI0518568A2 (pt) | 2004-12-24 | 2008-11-25 | Solvay Pharm Bv | mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico |
EP1856271A4 (fr) | 2005-03-08 | 2009-11-18 | Medimmune Vaccines Inc | Variants d'hemagglutinine et de neuraminidase du virus influenza |
JP5349049B2 (ja) | 2005-10-17 | 2013-11-20 | メディミューン,エルエルシー | インフルエンザウイルス製造用マルチプラスミド系 |
EA015271B1 (ru) | 2006-01-27 | 2011-06-30 | Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг | Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса |
AU2014202470B2 (en) | 2006-03-31 | 2016-08-04 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
EP2022849A4 (fr) | 2006-05-11 | 2010-10-06 | Chemo Sero Therapeut Res Inst | Procédé permettant une prolifération du virus de la grippe |
CN101983069B (zh) | 2006-08-09 | 2014-07-16 | 米迪缪尼有限公司 | 流感血凝素和神经氨酸酶变体 |
EP2615167A1 (fr) | 2006-09-15 | 2013-07-17 | MedImmune, LLC | Méthode d'élimination de contaminants d'ADN des préparations de virus |
US20110045022A1 (en) | 2006-12-06 | 2011-02-24 | Theodore Tsai | Vaccines including antigen from four strains of influenza virus |
PL2185191T3 (pl) | 2007-06-27 | 2013-02-28 | Novartis Ag | Szczepionki przeciwko grypie o małej zawartości dodatków |
RU2523587C2 (ru) | 2008-07-11 | 2014-07-20 | МЕДИММЬЮН, ЭлЭлСи | Варианты гемагглютинина и нейрамидазы вируса гриппа |
NZ596880A (en) | 2009-07-16 | 2013-10-25 | Crucell Holland Bv | Production of polio virus at high titers for vaccine production |
US9109013B2 (en) | 2009-10-26 | 2015-08-18 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
GB201011502D0 (en) | 2010-07-08 | 2010-08-25 | Glaxosmithkline Biolog Sa | Novel process |
WO2012033236A1 (fr) | 2010-09-06 | 2012-03-15 | 에스케이케미칼 주식회사 | Lignée cellulaire mdck adaptée pour culture sans sérum et culture en suspension, et procédé pour préparer des virus pour vaccin utilisant des cellules de celle-ci |
JP2016524915A (ja) | 2013-07-15 | 2016-08-22 | ウィスコンシン アルムニ リサーチ ファンデイション | Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス |
-
2007
- 2007-03-29 US US11/729,557 patent/US9254318B2/en active Active
- 2007-03-29 JP JP2009502945A patent/JP2009532352A/ja not_active Withdrawn
- 2007-03-29 CA CA2647985A patent/CA2647985C/fr active Active
- 2007-03-29 AU AU2007245192A patent/AU2007245192B2/en active Active
- 2007-03-29 CN CN200780020095.1A patent/CN101472941B/zh active Active
- 2007-03-29 EP EP07754132.4A patent/EP2010557B1/fr active Active
- 2007-03-29 WO PCT/US2007/007562 patent/WO2007126810A2/fr active Application Filing
-
2014
- 2014-03-12 JP JP2014049025A patent/JP2014131516A/ja not_active Withdrawn
-
2016
- 2016-01-19 US US15/000,851 patent/US9926535B2/en active Active
- 2016-06-02 JP JP2016110879A patent/JP6352974B2/ja active Active
-
2018
- 2018-02-26 US US15/905,454 patent/US20190048324A1/en not_active Abandoned
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
WO2000060050A2 (fr) | 1999-04-06 | 2000-10-12 | Wisconsin Alumni Research Foundation | Virus de l'influenza recombinants pour vaccins et traitement genetique |
US20030035814A1 (en) | 1999-04-06 | 2003-02-20 | Yoshihiro Kawaoka | Recombinant influenza viruses for vaccines and gene therapy |
JP2004500842A (ja) | 2000-04-28 | 2004-01-15 | セント・ジュード・チルドレンズ・リサーチ・ホスピタル | 感染性インフルエンザウイルスの発生のためのトランスフェクションシステム |
US8309099B2 (en) | 2000-04-28 | 2012-11-13 | St. Jude Children's Research Hospital | DNA transfection system for the generation of negative strand RNA virus |
WO2001083794A2 (fr) | 2000-04-28 | 2001-11-08 | St. Jude Children's Research Hospital | Systeme de transfection d'adn servant a generer des virus de la grippe infectieuse |
US20020164770A1 (en) | 2000-04-28 | 2002-11-07 | St. Jude Children's Research Hospital | DNA transfection system for the generation of infectious influenza virus |
EP1201760A1 (fr) | 2000-10-30 | 2002-05-02 | ARTEMIS Pharmaceuticals GmbH | Vecteur viral Influenza pour cellules dendritiques |
WO2003068923A2 (fr) | 2002-02-13 | 2003-08-21 | Wisconsin Alumni Research Foundation | Signal d'incorporation de vecteurs de virus de la grippe |
JP2005535288A (ja) | 2002-02-13 | 2005-11-24 | ウィスコンシン・アルムナイ・リサーチ・ファウンデーション | インフルエンザウイルスベクターのパッケージングのためのシグナル |
US7226774B2 (en) | 2002-02-13 | 2007-06-05 | Wisconsin Alumni Research Foundation | Signal for packaging of influenza virus vectors |
US20120020997A1 (en) | 2002-04-26 | 2012-01-26 | Erich Hoffman | Multi plasmid system for the production of influenza virus |
WO2003091401A2 (fr) | 2002-04-26 | 2003-11-06 | Medimmune Vaccines, Inc. | Systeme multiplasmide de production de virus influenza |
JP2005523698A (ja) | 2002-04-26 | 2005-08-11 | メディミューン・ヴァクシンズ・インコーポレーテッド | インフルエンザウイルスの生産用多重プラスミドシステム |
US8012736B2 (en) | 2002-04-26 | 2011-09-06 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
US8475806B2 (en) | 2003-05-28 | 2013-07-02 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines and gene therapy |
WO2004112831A2 (fr) | 2003-05-28 | 2004-12-29 | Wisconsin Alumni Research Foundation | Virus influenza de recombinaison a titre eleve pour vaccins et therapie genique |
US7037707B2 (en) * | 2003-09-04 | 2006-05-02 | St. Jude Children's Research Hospital | Method for generating influenza viruses and vaccines |
WO2005062820A2 (fr) | 2003-12-23 | 2005-07-14 | Medimmune Vaccines, Inc | Systeme a plasmides multiples pour la production du virus de la grippe |
JP2005245302A (ja) | 2004-03-04 | 2005-09-15 | Kanazawa Univ Tlo Inc | 組換えインフルエンザウイルスおよびそれを用いたワクチン |
WO2007126810A2 (fr) | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | Virus de la grippe recombinants à haut titre pour vaccins |
US20070231348A1 (en) * | 2006-03-31 | 2007-10-04 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
AU2012204138B2 (en) | 2006-03-31 | 2014-02-06 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
EP2010557B1 (fr) | 2006-03-31 | 2014-02-26 | Wisconsin Alumni Research Foundation | Virus de la grippe recombinants à haut titre pour vaccins |
JP2014131516A (ja) | 2006-03-31 | 2014-07-17 | Warf - Wisconsin Alumni Research Foundation | ワクチンのための高力価組み換えインフルエンザ・ウィルス |
US7507411B2 (en) * | 2006-06-23 | 2009-03-24 | University Of Saskatchewan | Attenuated influenza NS1 variants |
Non-Patent Citations (70)
Title |
---|
"Australian Application Serial No. 2007245192, Office Action mailed Aug. 25, 2011", 2 pgs. |
"Australian Application Serial No. 2007245192, Response filed Feb. 28, 2012 to Office Action mailed Aug. 25, 2011", 22 pgs. |
"Australian Application Serial No. 2012204138, First Examiner Report mailed Jul. 16, 2013", 4 pgs. |
"Australian Application Serial No. 2012204138, Response filed Dec. 24, 2013 to First Examiner Report mailed Jul. 16, 2013", 21 pgs. |
"Canadian Application Serial No. 2,647,985 , Response filed Sep. 30, 2013 Office Action mailed May 15, 2013", 20 pgs. |
"Canadian Application Serial No. 2,647,985, Office Action mailed May 15, 2013", 3 pgs. |
"Chinese Application Serial No. 200780020095.1, Decision on Rejection mailed Jul. 22, 2013", (w/ English Translation), 11 pgs. |
"Chinese Application Serial No. 200780020095.1, First Office Action mailed Jun. 24, 2011", (w/ English Translation), 13 pgs. |
"Chinese Application Serial No. 200780020095.1, Office Action mailed Jan. 29, 2013", (w/ English Translation), 10 pgs. |
"Chinese Application Serial No. 200780020095.1, Office Action mailed Mar. 5, 2015", (w/ English Translation), 12 pgs. |
"Chinese Application Serial No. 200780020095.1, Office Action mailed May 3, 2012", With English Translation, 10 pgs. |
"Chinese Application Serial No. 200780020095.1, Response filed Jun. 9, 2013 to Office Action mailed Jun. 29, 2013", (w/ English Translation of Claims), 10 pgs. |
"Chinese Application Serial No. 200780020095.1, Response filed Nov. 5, 2013 to to Decision on Rejection mailed Jul. 22, 2013", (w/ English Translation of Claims), 12 pgs. |
"Chinese Application Serial No. 200780020095.1, Response filed Nov. 8, 2011 to Office Action mailed Jun. 24, 2011", (w/ English Translation of Amended Claims), 20 pgs. |
"Chinese Application Serial No. 200780020095.1, Response filed Sep. 17, 2012 to Office Action mailed May 3, 2012", (w/ English Translation of Claims), 17 pgs. |
"Chinese Application Serial No. 2007800200951, Response filed Jun. 23, 2015 to Office Action mailed Mar. 5, 2015", (w/ English Translation of Claims), 16 pgs. |
"European Application Serial No. 07754132.4, Office Action mailed Apr. 28, 2009", 4 pgs. |
"European Application Serial No. 07754132.4, Office Action mailed Nov. 2, 2012", 4 pgs. |
"European Application Serial No. 07754132.4, Office Action mailed Sep. 5, 2011", 5 pgs. |
"European Application Serial No. 07754132.4, Response filed Feb. 5, 2010 to Office Action mailed Apr. 28, 2009", 15 pgs. |
"European Application Serial No. 07754132.4, Response filed Jun. 26, 2013", 8 pgs. |
"European Application Serial No. 07754132.4, Response filed Mar. 15, 2012 to Office Action mailed Sep. 5, 2011", 21 pgs. |
"European Application Serial No. 07754132.4, Response filed May 10, 2013 to Office Action mailed Nov. 2, 2012", 14 pgs. |
"Japanese Application Serial No. 2009-502945, Examiners Decision of Final Refusal mailed Nov. 12, 2013", (w/ English Translation), 8 pgs. |
"Japanese Application Serial No. 2009-502945, Office Action mailed Oct. 23, 2012", (w/ English Translation), 16 pgs. |
"Japanese Application Serial No. 2009-502945, Response filed Apr. 10, 2013 to Office Action mailed Oct. 23, 2012", (w/ English Translation of Claims), 18 pgs. |
"Japanese Application Serial No. 2014-049025, Office Action mailed Jun. 16, 2015", (w/ English Translation), 6 pgs. |
"PCT Application No. PCT/US2007/007562, International Search Report mailed Jan. 14, 2008", 8 pgs. |
"PCT Application No. PCT/US2007/007562, Written Opinion mailed Jan. 14, 2008", 9 pgs. |
"PCT Application Serial No. PCT/US2007/007562, International Preliminary Report on Patentability mailed Oct. 9, 2008", 5 pgs. |
Baez, M., et al., "Complete nucleotide sequence of the influenza A/PR/8/34 virus NS gene and comparison with the NS genes of the A/Udorn/72 and A/FPV/Rostock/34 strains", Nucleic Acids Research, 23(8), (1980), 5845-5858. |
Chen, H, et ai., "Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate", Vaccine, 21(17-18), (May 16, 2003), 1974-1979. |
De, B. P., et al., "Reverse Genetics of Negative Strand RNA Viruses", Indian Journal of Biochemistry & Biophysics, 31, (1994), 367-375. |
Dreher, T. W., et al., "Mutational Analysis of the Sequence and Structural Requirements in Brome Mosaic Virus RNA for Minus Strand Promoter Activity", Journal of Molecular Biology, 201(1), (1988), 31-40. |
Elliott, R. M., et al., "Rescue of Infectious Bunyavirus Entirely From Cloned cDNA", 10th International Conference on Negative Strand Virus, (Abstract No. 96), (1997), 1 pg. |
Fodor, E., "Rescue of Influenza A Virus from Recombinant DNA", Journal of Virology, 73(11), (1999), 9679-9682 |
Hoffmann, E. , et al., "A DNA Transfection System for Generation of Influenza A Virus from Eight Plasmids", Proceedings of the National Academy of Sciences of USA, National Academy of Science, 97(11), (2000), 6108-6113. |
Hoffmann, E., et al., "Ambisense Approach for the Generation of Influenza A Virus: vRNA and mRNA Synthesis from One Template", Virology, 267, (2000), 310-317. |
Hoffmann, E., et al., "Eight-plasmid System for Rapid Generation of Influenza Virus Vaccines", Vaccine, Butterworth Scientific Guildford, 20(25-56), (2002), 3165-3170. |
Hoffmann, E., et al., "Rescue of Influenza B Virus from Eight Plasmids", Proceedings of the National Academy of Sciences of USA, National Academy of Science, 99(17), (2002), 11411-11416. |
Holmes, E. C., et al., "Whole-Genome Analysis of Human Influenza A Virus Reveals Multiple Persistent Lineages and Reassortment Among Recent H3N2 Viruses", PLoS Biology, 3(9), (2005), 1579-1589. |
Horimoto, T., et al., "Generation of Influenza A Viruses with Chimeric (Type A/B) Hemagglutinins", Journal of Virology, 77(14), (2003), 8031-8038. |
Horimoto, T., et al., "The Development and Characterization of H5 Influenza Virus Vaccines Derived from a 2003 Human Isolate", Vaccine, 24(17), (2006), 3669-3676. |
Katinger, D., et al., "Attenuated Influenza Viruses as a Vector for Mucosal Immunization Against HIV-1", Vaccines, 97, Cold Spring Harbor,(1997), 315-319. |
Kiseleva et al., Role of individual genes of the A/Leningrad/134/17/57 (H2N2) cold-adapted donor strain in manifestation of the temperature-sensitive phenotype of reassortant influenza A viruses, 2004, International Congress Series, vol. 1263, pp. 547-550. * |
Lamb, R. A., et al., "Chapter 20-Paramyxoviridae: The Viruses and Their Replication", In: Fundamental Virology, Fields, B. N., et al., Editors, Lippincott-Raven (2nd Edition),(1996), 577-647. |
Lazarovits et al., Endocytosis of Chimeric Influenza Virus Hemagglutinin Proteins That Lack a Cytoplasmic Recognition Feature for Coated Pits, 1996, The Journal of Cell Biology, vol. 134, No. 2, pp. 339-348. * |
Lee et al., Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza, 2004, Vaccine, vol. 22, pp. 3175-3181. * |
Matsuoka et al., Neuraminidase Stalk Length and Additional Glycosylation of the Hemagglutinin Influence the Virulence of Influenza H5N1 Viruses for Mice, 2009, Journal of Virology, vol. 83, No. 9, pp. 4704-4708. * |
Muster et al., An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice, 1991, PNAS, vol. 88, pp. 5177-7181. * |
Muster et al., An influenza A virus containing influenza B virus 5′ and 3′ noncoding regions on the neuraminidase gene is attenuated in mice, 1991, PNAS, vol. 88, pp. 5177-7181. * |
Neumann, G., et al., "Generation of influenza A Virus from Cloned cDNAs-Historical Perspective and Outlook for the New Millenium", Reviews in Medical Virology, 12(1), (2002), 13-30. |
Neumann, G., et al., "Generation of Influenza A Viruses Entirely from Cloned cDNAs", Proc. Natl. Acad. Sci. USA, 96(16), (1999), 9345-9350. |
Neumann, G., et al., "Plasmid-Driven Formation of Influenza Virus-like Particles", Journal of Virology, The American Society For Microbiology, 74(1), (2000), 547-551. |
Odagiri, T., et al., "Nucleotide Sequence of the PA Gene of Influenza A/WSN/33 (H1N1)", Nucleic Acids Research, 18(3), Department of Virology, (1990), p. 654. |
Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995, downloaded on Sep. 5, 2008 from . * |
Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995, downloaded on Sep. 5, 2008 from <http://www.nih.gov/news/panelrep.html>. * |
PCT Application No. PCT/US2004/016680, International Search Report mailed Feb. 2, 2005, 7 pgs. |
Result 1, NCBI Blast nucleotide search of SEQ ID No. 3, database "nr"; Result 4, NCBI Blast nucleotide search of SEQ ID No. 4, database "nr", (Jul. 22, 2006), 11 pgs. |
Result 17, NCBI Blast nucleotide search of SEQ ID No. 2, database "nr", (Jul. 18, 2006), 3 pgs. |
Result 2, NCBI Blast nucleotide search of SEQ ID No. 5, database "nr"; Result 4, NCBI Blast nucleotide search of SEQ ID No. 6, database "nr", (Jul. 22, 2006), 6 pgs. |
Result 7, NCBI Blast nucleotide search of SEQ ID No. 1, database "nr", (Jul. 18, 2006), 3 pgs. |
Results 1, NCBI Blast nucleotide search of SEQ ID No. 7, database "nr"; Result 1, NCBI Blast nucleotide search of SEQ ID No. 8, database "Jul. 23, 2006", (Jul. 23, 2006), 8 pgs. |
Schickli, J. H., et al., "Plasmid-only Rescue of Influenza A Virus Vaccine Candidates", Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 356(1416), (2001), 1965-1973. |
Smeenk, et al., "Mutations in the Hemagglutinin and Matrix Genes of a Virulent Influenza Virus Variant, A/FM/1/47-MA, Control Different Stages in Pathogenesis", Virus Research 44, (1996) ,79-95. |
Subbarao, K., et al., "Evaluation of a Genetically Modified Reassortant H5N1 Influenza A Virus Vaccine Candidate Generated by Plasmid-based Reverse Genetics", Virology, vol. 30(1), (2003), 192-200. |
Verma et al., Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389, pp. 239-242. * |
Voeten et al., Characterization of high-growth reassortant infuenza A virus generated in MDCK cells cultured in serum-free medium, 1999, Vaccine, vol. 17, pp. 1942-1950. * |
Winter, G., et al., "The use of synthetic oligodeoxynucleotide primers in cloning and sequencing segment 8 of influenza virus (A/PR/8/34)", Nucleic Acids Research, 9(2), (1981), 237-245. |
Yannarell et al., Factors affecting the yield of cold-adapted influenza virus vaccine, 1997, Journal of Virological Methods, vol. 64, pp. 161-169. * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9926535B2 (en) | 2006-03-31 | 2018-03-27 | Wisconsin Alumni Research Foundation (Warf) | High titer recombinant influenza viruses for vaccines |
US10119124B2 (en) | 2007-06-18 | 2018-11-06 | Wisconsin Alumni Research Foundation (Warf) | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
US10808229B2 (en) | 2009-10-26 | 2020-10-20 | Wisconsin Alumni Research Foundation (“WARF”) | High titer recombinant influenza viruses with enhanced replication in vero cells |
US11007262B2 (en) | 2010-03-23 | 2021-05-18 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
US9950057B2 (en) | 2013-07-15 | 2018-04-24 | Wisconsin Alumni Research Foundation (Warf) | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs |
US10172934B2 (en) | 2013-07-15 | 2019-01-08 | Wisconsin Alumni Research Foundation (Warf) | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs |
US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US11802273B2 (en) | 2014-06-20 | 2023-10-31 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US11046934B2 (en) | 2014-06-20 | 2021-06-29 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
US10246686B2 (en) | 2015-07-06 | 2019-04-02 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
US11241492B2 (en) | 2019-01-23 | 2022-02-08 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to genes in influenza viruses |
US11851648B2 (en) | 2019-02-08 | 2023-12-26 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
Also Published As
Publication number | Publication date |
---|---|
EP2010557B1 (fr) | 2014-02-26 |
EP2010557A2 (fr) | 2009-01-07 |
WO2007126810A2 (fr) | 2007-11-08 |
US20070231348A1 (en) | 2007-10-04 |
US20190048324A1 (en) | 2019-02-14 |
CN101472941B (zh) | 2017-08-08 |
WO2007126810A3 (fr) | 2008-03-13 |
JP2014131516A (ja) | 2014-07-17 |
AU2007245192A1 (en) | 2007-11-08 |
AU2007245192B2 (en) | 2012-04-12 |
JP6352974B2 (ja) | 2018-07-04 |
CA2647985A1 (fr) | 2007-11-08 |
US20160208223A1 (en) | 2016-07-21 |
JP2009532352A (ja) | 2009-09-10 |
CN101472941A (zh) | 2009-07-01 |
CA2647985C (fr) | 2014-12-30 |
JP2016169225A (ja) | 2016-09-23 |
US9926535B2 (en) | 2018-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9926535B2 (en) | High titer recombinant influenza viruses for vaccines | |
US8475806B2 (en) | High titer recombinant influenza viruses for vaccines and gene therapy | |
US10808229B2 (en) | High titer recombinant influenza viruses with enhanced replication in vero cells | |
US10172934B2 (en) | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs | |
AU2012204138B2 (en) | High titer recombinant influenza viruses for vaccines | |
AU2014202470B2 (en) | High titer recombinant influenza viruses for vaccines | |
US10246686B2 (en) | Influenza virus replication for vaccine development | |
US11390649B2 (en) | Influenza virus replication for vaccine development | |
KAWAOKA | Patent 2525953 Summary | |
MXPA05012712A (en) | High titer recombinant influenza viruses for vaccines and gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF WISCONSIN-MADISON;REEL/FRAME:022002/0393 Effective date: 20070722 |
|
AS | Assignment |
Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION,WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KAWAOKA, YOSHIHIRO;REEL/FRAME:024018/0867 Effective date: 20100302 Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION, WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KAWAOKA, YOSHIHIRO;REEL/FRAME:024018/0867 Effective date: 20100302 |
|
AS | Assignment |
Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION, WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HORIMOTO, TAISUKE;REEL/FRAME:025442/0474 Effective date: 20101118 |
|
AS | Assignment |
Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION, WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MURAKAMI, SHIN;REEL/FRAME:025618/0310 Effective date: 20101029 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |
|
CC | Certificate of correction | ||
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |